摘要
目的 探讨中国类风湿关节炎(RA)患者疾病活动度与健康效用值之间的关联,并分析可能影响健康效用值的其他因素,为RA患者的个体化治疗和健康管理提供依据。方法 本研究基于中国类风湿关节炎直报项目(CREDIT),纳入分析1 017例确诊RA患者。通过EQ-5D-3L量表评估患者的健康效用值,同时收集患者的临床资料、疾病活动度以及潜在的影响因素(如年龄、性别、合并症等)。Tobit回归模型用于分析疾病活动度与健康效用值之间的关联,并探讨其他可能的影响因素。结果 RA患者的健康效用值中位数为0.78[0.59,0.89],其中中高疾病活动度患者的健康效用值显著低于缓解或低活动度患者(中位数0.70 vs. 0.87,P<0.001)。Tobit回归分析显示,疾病活动度与健康效用值之间存在显著关联(P<0.001),此外,年龄大、女性患者、使用激素治疗以及合并糖尿病的患者健康效用值较低(P<0.05)。结论 RA患者的健康效用值与疾病活动度密切相关,疾病活动度较高的患者健康效用值显著下降。早期控制RA疾病活动度有助于提高患者的生活质量。
Objective To explore the association between disease activity and health utility values(HUV)in patients with rheumatoid arthritis(RA)in China,and to analyze other factors that may affect health utility values,providing a basis for individualized treatment and health management for RA patients.Methods Based on the Chinese Registry of Rheumatoid arthritis cohort,this study included 1017 diagnosed RA patients.The EQ-5D-3L scale was used to assess the health utility values,while clinical data,disease activity,and potential influencing factors(such as age,gender,and comorbidities)were collected.Tobit regression models were employed to analyze the association between disease activity and health utility values,and to investigate other potential influencing factors.Results The median health utility value for RA patients was 0.78[0.59,0.89].Patients with moderate to high disease activity had significantly lower health utility values as compared to those in remission phase or with low disease activity(median 0.70 vs.0.87,P<0.001).Tobit regression analysis showed a significant association between disease activity and health utility values(P<0.001).Additionally,older age,female gender,use of glucocorticoids,and comorbidity with diabetes were associated with lower health utility values(P<0.05).Conclusions Health utility values of RA patients are closely related to disease activity,with higher disease activity leading to a significant reduction in health utility values.Early control of RA disease activity may help improve patients′quality of life.
作者
余兵
李路
李梦涛
王艳红
YU Bing;LI Lu;LI Mengtao;WANG Yanhong(Department of Epidemiology and Biostatistics,Institute of Basic Medical Sciences Chinese Academy of Medical Sciences,School of Basic Medicine Peking Union Medical College,Beijing 100005;Department of Rheumatology and Clinical Immunology,National Clinical Research Center for Dermatologic and Immunologic Diseases(NCRC-DID),State Key Laboratory of Complex Severe and Rare Diseases,Key Laboratory of Rheumatology and Clinical Immunology,Ministry of Education,Peking Union Medical College Hospital,CAMS&PUMC,Beijing 100730,China)
出处
《基础医学与临床》
2025年第6期762-769,共8页
Basic and Clinical Medicine
基金
中国医学科学院医学与健康科技创新工程(2019-I2M-2-008)。
